This Article Full Text (PDF) All Versions of this Article: 1352458507078064v1 13/8/955    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Holley, J.E. Articles by Gutowski, N.J. Search for Related Content PubMed PubMed Citation Articles by Holley, J.E. Articles by Gutowski, N.J. Social Bookmarking                         What's this?

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

Institute of Biomedical and Clinical Science, Peninsula Medical School (Exeter), and Royal Devon and Exeter Hospital, Devon, UK, janet.holley{at}pms.ac.uk

J. Newcombe

NeuroResource, Department of Neuroinflammation, UCL Institute of Neurology, London, UK

P.G. Winyard

Institute of Biomedical and Clinical Science, Peninsula Medical School (Exeter), and Royal Devon and Exeter Hospital, Devon, UK

N.J. Gutowski

Institute of Biomedical and Clinical Science, Peninsula Medical School (Exeter), and Royal Devon and Exeter Hospital, Devon, UK

Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical production intensifies, and is protective in an animal model of brain injury. However, little is known about PRDX V expression in the human brain. We investigated PRDX V expression in white matter from normal human brain (n = 5) and MS patients (n = 18), using immunohistochemistry and immunoblotting. A global increase in PRDX V was evident in MS normal-appearing white matter (NAWM) but the most striking increase was in astrocytes in MS lesions. PRDX V- positive hypertrophic reactive astrocytes were seen in acute lesions where inflammation was present. Yet surprisingly, in chronic lesions (CL), where inflammation has abated and a glial scar formed, there was strong PRDX V staining of post-reactive, scar astrocytes. Furthermore, immunoblotting analysis of tissue from two MS cases confirmed a substantial increase in PRDX V expression in CL compared with NAWM from the same individual. This might indicate ongoing oxidative stress despite the absence of histologically defined inflammation. Further investigations of this phenomenon will be of interest for therapeutic targeting. Multiple Sclerosis 2007; 13: 955—961. http://msj.sagepub.com

Key Words: antioxidants • astrocyte • human brain • multiple sclerosis • oxidative damage • peroxiredoxins

This version was published on September 1, 2007

Multiple Sclerosis, Vol. 13, No. 8, 955-961 (2007)
DOI: 10.1177/1352458507078064


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?